Astrotech Reports Third Quarter of Fiscal Year 2022 Financial Results

Rhea-AI Summary

Astrotech Corporation (Nasdaq: ASTC) reported impressive financial results for Q3 FY 2022, ending March 31, with TRACER 1000 sales soaring 161% year-to-date to $845K. The TRACER 1000, certified by ECAC for air security, showed an 80% revenue increase compared to last year. Gross profit surged to 53%. The AgLAB-1000-D2 successfully completed field trials, enhancing THC and CBD oil yields. Additionally, pre-clinical trials for the BreathTest-1000, aimed at detecting lung infections, are set to begin at Cleveland Clinic, marking significant advancements for Astrotech.

Positive

• TRACER 1000 revenue up 161% year-to-date to $845K.
• Gross profit increased to 53% from 15% in the prior period.
• Successful field trials of AgLAB-1000-D2 enhancing THC and CBD oil yields.
• First TRACER 1000 systems installed in the Philippines.

Negative

• None.

AUSTIN, Texas--(BUSINESS WIRE)-- Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) reported its financial results for the third quarter of fiscal year 2022, which ended March 31, 2022.

Astrotech's subsidiary 1^st Detect continues sales of its TRACER 1000™ solution, the first and only mass spectrometry-based explosives trace detector (ETD) certified by the European Civil Aviation Conference (ECAC) for air and cargo security, with revenue related to the TRACER 1000 up 161% to $845 thousand for the nine months ended March 31, 2022, compared to the same period one year ago. The TRACER 1000’s near-zero false alarm rate leads to high desirability in the cargo security market, as an alarm can cause costly shutdowns at cargo facilities while the potential threat is investigated. Interest also remains high in the airport checkpoint security market after 1^st Detect completed installation of eight TRACER 1000 systems in an airport in the Philippines earlier this year.

At AgLAB, recent successful field trials demonstrated that the AgLAB-1000-D2™ can be used in the distillation process to significantly boost the potency and weight yields of THC and CBD oil manufacturing. This development will allow us to launch a family of “process control” instruments, methods, and solutions that we believe will be very beneficial to many nutraceutical extraction and distillation laboratories.

We announced on February 2, 2022, that Dr. Karim Sirgi, MD, MBA and FCAP has joined BreathTech Corporation as its Chief Science Officer. Dr. Sirgi will help lead our research and development and regulatory efforts as BreathTech looks to commercialize the BreathTest-1000™ to help in the battle against lung infections, including COVID-19 and pneumonia. The BreathTest-1000 is designed to screen for volatile organic compound (VOC) metabolites found in a person’s breath indicating the presence of a lung infection.

“1^st Detect has delivered strong revenue growth with revenue up over 100% from last fiscal year, led by continued sales of our TRACER 1000 ETD to the cargo security and passenger checkpoint screening markets. We achieved a key milestone with our first systems installed in the Philippines earlier this year and we look forward to increasing our ability to service our growing list of customers,” stated Thomas B. Pickens III, Chairman and Chief Executive Officer of Astrotech. "We also look forward to delivering the AgLAB-1000 to the market in the near-term as we believe customer interest remains high. Nutraceutical processors are searching for a solution to streamline and automate their extraction and distillation methods as a way to increase their efficiencies and revenues. Finally, our collaboration with Cleveland Clinic to develop the BreathTest-1000 is well underway with clinical trials on the horizon. We believe that the ability of our technology to detect not only COVID-19, but many other diseases that express VOCs through the lungs, will differentiate our product line from any other breath analysis systems," concluded Mr. Pickens.

Third Quarter Fiscal Year 2022 Highlights

Management continues efforts to accelerate growth and optimize resources.

• Astrotech’s balance sheet remains strong with $55 million in cash and liquid investments which is anticipated to support our expected organic growth and acquisition opportunities.
• For the third quarter, revenue for the TRACER 1000 is up 80% compared to the same period one year ago, and 161% fiscal year-to-date compared to the same period one year ago.
• Gross profit increased to 53% for the quarter compared to 15% in the prior period.
• The AgLAB-1000-D2 has completed its cannabis oil processing field trials with excellent results.
• The BreathTest-1000 pre-clinical trials are being held at Cleveland Clinic and they will soon be underway with an experienced team assembled to lead the effort.
• The transition to contract manufacturing by Sanmina is now complete.

About Astrotech Corporation

Astrotech (NASDAQ: ASTC) is a mass spectrometry company that launches, manages, and commercializes scalable companies based on its innovative core technology through its wholly-owned subsidiaries. 1^st Detect develops, manufactures, and sells trace detectors for use in the security and detection market. AgLAB is developing chemical analyzers for use in the agriculture market. BreathTech is developing a breath analysis tool to provide early detection of lung diseases. Astrotech is headquartered in Austin, Texas. For information, please visit www.astrotechcorp.com.

About the AgLAB-1000™ and the BreathTest-1000™

This press release contains information about our new products under development, AgLAB-1000 and BreathTest-1000. Product development involves a high degree of risk and uncertainty, and there can be no assurance that our new products will be successfully developed, achieve their intended benefits, receive full market authorization, or be commercially successful. In addition, FDA approval will be required to market BreathTest-1000 in the United States. Obtaining FDA approval is a complex and lengthy process, and there can be no assurance that FDA approval for BreathTest-1000 will be granted on a timely basis or at all.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These factors include, but are not limited to, the severity and duration of the COVID-19 pandemic and its impact on the U.S. and worldwide economy, the timing, scope and effect of further U.S. and international governmental, regulatory, fiscal, monetary and public health responses to the COVID-19 pandemic, the Company’s use of proceeds from the common stock offerings, whether we can successfully complete the development of our new products and proprietary technologies, whether we can obtain the FDA and other regulatory approvals required to market our products under development in the United States or abroad, whether the market will accept our products and services and whether we are successful in identifying, completing and integrating acquisitions, as well as other risk factors and business considerations described in the Company’s Securities and Exchange Commission filings including the Company’s most recent Annual Report on Form 10-K. Any forward-looking statements in this document should be evaluated in light of these important risk factors. Although the Company believes the expectations reflected in its forward-looking statements are reasonable and are based on reasonable assumptions, no assurance can be given that these assumptions are accurate or that any of these expectations will be achieved (in full or at all) or will prove to have been correct. Moreover, such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company assumes no obligation to correct or update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Tables follow

 

ASTROTECH CORPORATION Consolidated Statements of Operations and Comprehensive Loss (In thousands, except per share data)
		Three Months Ended								Nine Months Ended
		March 31,								March 31,
		2022				2021				2022				2021
Revenue		$	97			$	54			$	845			$	324
Cost of revenue			46				46				662				287
Gross profit			51				8				183				37
Operating expenses:
Selling, general and administrative			1,476				1,679				4,630				3,408
Research and development			722				669				2,013				2,036
Disposal of corporate lease			—				—				—				544
Total operating expenses			2,198				2,348				6,643				5,988
Loss from operations			(2,147	)			(2,340	)			(6,460	)			(5,951	)
Other income and (expense), net			47				(63	)			151				(185	)
Loss from operations before income taxes			(2,100	)			(2,403	)			(6,309	)			(6,136	)
Income tax benefit			—				—				—				—
Net loss		$	(2,100	)		$	(2,403	)		$	(6,309	)		$	(6,136	)
Weighted average common shares outstanding:
Basic and diluted			47,611				18,171				47,506				14,649
Basic and diluted net loss per common share:
Net loss		$	(0.04	)		$	(0.13	)		$	(0.13	)		$	(0.42	)
Other comprehensive loss, net of tax:
Net loss		$	(2,100	)		$	(2,403	)		$	(6,309	)		$	(6,136	)
Available-for-sale securities:
Net unrealized loss			(524	)			—				(769	)			—
Total comprehensive loss		$	(2,624	)		$	(2,403	)		$	(7,078	)		$	(6,136	)

 

ASTROTECH CORPORATION Consolidated Balance Sheets (In thousands, except share data)
		March 31,				June 30,
		2022				2021
		(Unaudited)				(Note)
Assets
Current assets
Cash and cash equivalents		$	28,346			$	35,936
Short-term investments			26,580				27,351
Accounts receivable			140				5
Inventory, net:
Raw materials			1,140				1,056
Work-in-process			17				147
Finished goods			341				297
Prepaid expenses and other current assets			579				318
Total current assets			57,143				65,110
Property and equipment, net			917				263
Operating leases, right-of-use assets, net			184				249
Other assets			11				11
Total assets		$	58,255			$	65,633
Liabilities and stockholders’ equity
Current liabilities
Accounts payable			107				396
Payroll related accruals			899				344
Accrued expenses and other liabilities			859				888
Income tax payable			2				2
Term note payable - related party			500				2,500
Lease liabilities, current			231				81
Total current liabilities			2,598				4,211
Lease liabilities, net of current portion			362				215
Total liabilities			2,960				4,426
Commitments and contingencies
Stockholders’ equity
Convertible preferred stock, $0.001 par value, 2,500,000 shares authorized; 280,898 shares of Series D issued and outstanding at March 31, 2022 and June 30, 2021			—				—
Common stock, $0.001 par value, 250,000,000 and 50,000,000 shares authorized at March 31, 2022 and June 30, 2021, respectively; 49,569,113 and 49,450,558 shares issued and outstanding at March 31, 2022 and June 30, 2021, respectively			190,641				190,641
Additional paid-in capital			79,137				77,971
Accumulated deficit			(213,691	)			(207,382	)
Accumulated other comprehensive loss			(792	)			(23	)
Total stockholders’ equity			55,295				61,207
Total liabilities and stockholders’ equity		$	58,255			$	65,633

Note: The balance sheet at June 30, 2021, has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by the United States generally accepted accounting principles for complete financial statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220512005337/en/

Jaime Hinojosa, Chief Financial Officer, Astrotech Corporation, (512) 485-9530

 

Source: Astrotech Corporation

FAQ

What are the financial results for Astrotech Corporation (ASTC) for Q3 FY 2022?

Astrotech reported a TRACER 1000 revenue increase of 161% year-to-date, totaling $845K, with a gross profit rise to 53%.

What developments have occurred with the TRACER 1000 security system by ASTC?

The TRACER 1000 saw an 80% revenue increase for Q3 compared to the same period last year, and it has been installed at an airport in the Philippines.

What is the purpose of the BreathTest-1000 launched by ASTC?

The BreathTest-1000 aims to detect lung infections such as COVID-19 and pneumonia by screening breath for specific volatile organic compound metabolites.

What are the next steps for the AgLAB-1000-D2 from Astrotech?

Following successful field trials, Astrotech plans to launch the AgLAB-1000-D2 to enhance efficiency in THC and CBD oil extraction.